Severine Sarp
Novartis
15 Papers
29 Citations
Severine Sarp is an academic researcher from Novartis. The author has contributed to research in topics: Medicine & Lapatinib. The author has an hindex of 6, co-authored 12 publications.
Chat about Author
Papers
Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2–Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial
Amir Sonnenblick,Dominique Agbor-Tarh,Ian Bradbury,Serena Di Cosimo,Hatem A. Azim,Debora Fumagalli,Severine Sarp,Antonio C. Wolff,Martin Andersson,Judith R. Kroep,Tanja Cufer,Sergio Daniel Simon,Pamela Salman,Masakazu Toi,Lyndsay Harris,Julie Gralow,Maccon M. Keane,Alvaro Moreno-Aspitia,Martine Piccart-Gebhart,Evandro de Azambuja +19 more
TL;DR: Whereas insulin treatment was associated with a detrimental effect, metformin had a salutary effect in patients with diabetes who had HER2-positive and hormone receptor-positive breast cancer.
Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.
Jens Huober,Eileen Holmes,José Baselga,Evandro de Azambuja,Michael Untch,Debora Fumagalli,Severine Sarp,István Láng,Ian E. Smith,Frances M. Boyle,Binghe Xu,Christophe Lecocq,Hans Wildiers,Christelle Jouannaud,John Hackman,Lokanatha Dasappa,Eva Ciruelos,Juan Carlos Toral Pena,Hryhoriy Adamchuk,Tamas Hickish,Lorena de la Peña,Christian Jackisch,Richard D. Gelber,Martine Piccart-Gebhart,Serena Di Cosimo +24 more
TL;DR: Achieving a pCR is important in HER2-positive early breast cancer and translates into better long-term outcome with regard to event-free survival and OS, and in landmark analyses, patients with a p CR had a significantly higher 6-year EFS and OS compared with those without one.
78
Are all quantitative postmarketing signal detection methods equal? Performance characteristics of logistic regression and Multi-item Gamma Poisson Shrinker.
Conny Berlin,Carles Blanch,David J. Lewis,Dionigi D. Maladorno,Christiane Michel,Michael Petrin,Severine Sarp,Philippe Close +7 more
TL;DR: Novartis has adopted a novel system for automated signal detection on the basis of disproportionality methods within a safety data mining application that uses two algorithms for routine analyses: empirical Bayes Multi‐item Gamma Poisson Shrinker and logistic regression (LR).
21
Increasing Use of Compassionate Use/Managed Access Channels to Obtain Medicines for Use in COVID-19.
TL;DR: The Novartis Managed Access activity for COVID-19 delivered unapproved/repurposed medicines to nearly 6,000 patients over a 6-month period.
11
International Country-Level Trends, Factors, and Disparities in Compassionate Use Access to Unlicensed Products for Patients With Serious Medical Conditions
P Aliu,Severine Sarp,Ramona Reichenbach,Sigrid Behr,P. Michelle Fitzsimmons,Mansurahmad Shamlajee,Surya Prakash Kola,Samantha Nunes Radimerski,Emil Scosyrev +8 more
TL;DR: In this article , the disparity in compassionate use access observed across countries and explores the key driving factors for the disparity, and examines the key factors that contribute to this disparity. But the disparity is not discussed in detail.